BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Masimo Corporation (MASI) Study Shows Noninvasive SpCO® Can Help Rapidly Detect Carbon Monoxide Poisoning in the Emergency Department


5/21/2013 9:04:17 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

IRVINE, Calif., May 21, 2013 /PRNewswire/ – Masimo (NASDAQ:MASI) announced today that a new clinical study posted online in Respiratory Care confirms the clinical utility of Masimo’s noninvasive carboxyhemoglobin (SpCO®) from rainbow® Pulse CO-Oximetry™ as a first-line assessment tool in helping clinicians rapidly detect carbon monoxide (CO) poisoning.1

CO poisoning accounts for an estimated 50,000 emergency department (ED) visits in the U.S. annually and is the leading cause of accidental poisoning death.2 Symptoms of CO poisoning include headache, dizziness, nausea/vomiting, confusion, fatigue, chest pain, shortness of breath, and loss of consciousness, but are often attributed to other illnesses such as the flu. Failure to diagnose CO poisoning can have disastrous consequences for patients and potentially other family members of the affected household.3 Unfortunately, only about half (50%) of U.S. acute care hospitals have laboratory CO-oximetry capabilities enabling confirmation of CO poisoning in the blood,4 likely due to the expense of the instrumentation. Additional delays occur if a patient needs hyperbaric oxygen therapy, which often requires transfer to yet another medical center with hyperbaric capability.

Previous studies have shown that SpCO can help clinicians increase CO poisoning detection by as much as 39%5 and is associated with a shorter time to initiation of treatment (4.4 vs. 5.3 hours) with hyperbaric oxygen.6 These data have previously led to suggestions that SpCO could be used as a tool to help determine whether an invasive blood measurement of carboxyhemoglobin (COHb) should be performed to confirm CO intoxication.7

Researchers at Departement des urgencies, Centre Hospitalier Regional Universitaire Lapeyronie in Montpellier, France, studied 93 consecutive patients suspected of CO exposure presenting to an urban-based university hospital ED. Patients were tested noninvasively with a Masimo Rad-57™ Pulse CO-Oximeter®, while simultaneous blood samples were taken for laboratory COHb analysis and comparison.

Diagnosis of CO poisoning was determined for 26 (28%) patients. Compared to laboratory COHb values, the bias and standard deviation of SpCO over all patients was -0.2% +/- 3.3%. In six subjects with very high COHb values (greater than 15%), the bias and standard deviation of SpCO was 1.2% +/- 2.2%. The area under the curve for SpCO’s ability to detect CO poisoning, which takes into account both sensitivity and specificity, was 0.83 for non-smokers and 0.98 for smokers, with an optimal SpCO threshold of 6% for non-smokers and 9% for smokers.

Researchers concluded “noninvasive Pulse CO-Oximetry could be useful as a first-line screening test, enabling rapid detection and management of CO-poisoned patients in the ED.”

1 Sebbane M, Claret PG, Mercier G, Lefebvre S, Thery R, Dumont R, et al. “Emergency Department Management of Suspected Carbon Monoxide Poisoning: Role of Pulse Co-Oximetry.” Respir Care. Published online ahead of print Mar 19, 2013. Available here

2 Hampson N., Weaver L. “Carbon Monoxide Poisoning: A New Incidence for an Old Disease.” Undersea Hyperb Med 2007;34:163-168. Available online here

3 Hampson N., Piantadosi C., Thom S., Weaver L. “Practice Recommendations in the Diagnosis, Management, and Prevention of Carbon Monoxide Poisoning,” American Journal of Respiratory and Critical Care Medicine, Vol. 186, No. 11 (2012), pp. 1095-1101. Available online here

4 Hampson NB, Scott KL, Zmaeff JL. “Carboxyhemoglobin measurement by hospitals: Implications for the diagnosis of carbon monoxide poisoning.” J Emerg Med 2006;31(1):13-6. Available online here

5 Suner S, Partridge R, Sucov A, et al. “Noninvasive Pulse CO-Oximetry Screening in the Emergency Department Identifies Occult Carbon Monoxide Toxicity.” J. Emerg Med. 2008; 34(4): 441-450.

6 Hampson N. “Noninvasive pulse CO-oximetry expedites evaluation and management of patients with carbon monoxide poisoning.” The American Journal of Emergency Medicine 2012 (10.1016/j.ajem.2012.03.026) Available online here

7 Zaouter C, Zavorsky G. “The measurement of carboxyhemoglobin and methemoglobin using a noninvasive pulse CO-oximeter.” Respiratory Physiology & Neurobiology July 2012. Available online here

About Masimo

Masimo (NASDAQ:MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of “Improving Patient Outcome and Reducing Cost of Care…by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at www.masimo.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES